To study the effects of zinc gluconate supplementation on patients with Behçet's syndrome, 50 patients will be randomly allocated to two groups: placebo group or zinc group (one tablet of 30 mg/day elemental zinc) for 12 weeks. All participants will be asked not to alter their diet, medication, and physical activity during the study. At the first and the end of the intervention, genes and proteins expression, the serum level of inflammatory factors, quality of life, disease activity, anthropometric measures, physical activity and serum level of zinc will be assessed and compared between groups.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Toll-like Receptor-2 gene expression
Timeframe: 12 weeks
Toll-like Receptor-4 gene expression
Timeframe: 12 weeks
Toll-like Receptor-2 protein expression
Timeframe: 12 weeks
Toll-like Receptor-4 protein expression
Timeframe: 12 weeks
Serum level of tumor necrosis factor-alpha
Timeframe: 12 weeks
NLRP3 gene expression
Timeframe: 12 weeks
Caspase-1 gene expression
Timeframe: 12 weeks
Serum level of interleukin-1 beta
Timeframe: 12 weeks
Serum level of zinc
Timeframe: 12 weeks